Zika virus infection during pregnancy can cause congenital microcephaly and brain abnormalities (1), and detection of Zika virus RNA in clinical and tissue specimens can provide definitive laboratory evidence of recent Zika virus infection. Whereas duration of viremia is typically short, prolonged detection of Zika virus RNA in placental, fetal, and neonatal brain tissue has been reported and can provide key diagnostic information by confirming recent Zika virus infection (2). In accordance with recent guidance (3,4), CDC provides Zika virus testing of placental and fetal tissues in clinical situations where this information could add diagnostic value. This report describes the evaluation of formalin-fixed paraffin-embedded (FFPE) tissue specimens tested for Zika virus infection in 2016 and the contribution of this testing to the public health response. Among 546 live births with possible maternal Zika virus exposure, for which placental tissues were submitted by the 50 states and District of Columbia (DC), 60 (11%) were positive by Zika virus reverse transcription-polymerase chain reaction (RT-PCR). Among 81 pregnancy losses for which placental and/or fetal tissues were submitted, 18 (22%) were positive by Zika virus RT-PCR. Zika virus RT-PCR was positive on placental tissues from 38/363 (10%) live births with maternal serologic evidence of recent unspecified flavivirus infection and from 9/86 (10%) with negative maternal Zika virus immunoglobulin M (IgM) where possible maternal exposure occurred >12 weeks before serum collection. These results demonstrate that Zika virus RT-PCR testing of tissue specimens can provide a confirmed diagnosis of recent maternal Zika virus infection.
Zika virus infection during pregnancy can cause congenital microcephaly and brain abnormalities (1) , and detection of Zika virus RNA in clinical and tissue specimens can provide definitive laboratory evidence of recent Zika virus infection. Whereas duration of viremia is typically short, prolonged detection of Zika virus RNA in placental, fetal, and neonatal brain tissue has been reported and can provide key diagnostic information by confirming recent Zika virus infection (2) . In accordance with recent guidance (3, 4) , CDC provides Zika virus testing of placental and fetal tissues in clinical situations where this information could add diagnostic value. This report describes the evaluation of formalin-fixed paraffin-embedded (FFPE) tissue specimens tested for Zika virus infection in 2016 and the contribution of this testing to the public health response. Among 546 live births with possible maternal Zika virus exposure, for which placental tissues were submitted by the 50 states and District of Columbia (DC), 60 (11%) were positive by Zika virus reverse transcription-polymerase chain reaction (RT-PCR). Among 81 pregnancy losses for which placental and/or fetal tissues were submitted, 18 (22%) were positive by Zika virus RT-PCR. Zika virus RT-PCR was positive on placental tissues from 38/363 (10%) live births with maternal serologic evidence of recent unspecified flavivirus infection and from 9/86 (10%) with negative maternal Zika virus immunoglobulin M (IgM) where possible maternal exposure occurred >12 weeks before serum collection. These results demonstrate that Zika virus RT-PCR testing of tissue specimens can provide a confirmed diagnosis of recent maternal Zika virus infection.
Zika virus RT-PCR and, in selected cases, immunohistochemical (IHC) testing, were performed at CDC's Infectious Diseases Pathology Branch (IDPB) on FFPE tissue specimens submitted from completed pregnancies (i.e., live births and pregnancy losses of any gestational age) with possible maternal Zika virus exposure.* Completed pregnancies in this report include those with evidence * Possible exposure to Zika virus includes: 1) travel to or residence in an area at risk for Zika virus transmission and with a CDC travel notice, or 2) condomless sexual exposure to a partner who traveled to or lived in an area with risk of Zika virus transmission and a CDC travel notice during pregnancy or the periconceptional period (https://www.cdc.gov/zika/geo/index.html (2, (6) (7) (8) .
During 2016, tissue specimens from 627 completed pregnancies with possible maternal Zika virus exposure from the 50 states and DC were submitted to CDC and were tested by Zika virus tissue RT-PCR. These specimens included placental tissues from 546 live births and placental and/or fetal tissues from 81 pregnancy losses; IHC testing for Zika virus was also performed on specimens from 91 live births and pregnancy ** Birth defects include those that met the USZPR surveillance case definition for birth defects potentially associated with Zika virus infection during pregnancy as of May 18, 2017. These birth defects include brain abnormalities and/or microcephaly; intracranial calcifications; ventriculomegaly; neural tube defects and other early brain malformations; eye abnormalities; or other consequences of central nervous system dysfunction including arthrogryposis (joint contractures), clubfoot, congenital hip dysplasia, and congenital deafness (https://www.cdc.gov/zika/geo/pregnancy-outcomes.html).
losses (15%), criteria for which are specified below. Overall, 78/627 (12%) had one or more placental or fetal tissue specimen that was positive for Zika virus by RT-PCR. Among the 91 completed pregnancies with tissue specimens tested by IHC, seven (8%) demonstrated IHC evidence of Zika virus infection (six from first trimester pregnancy losses and one from a second trimester pregnancy loss). All seven IHC-positive pregnancy losses were also tissue RT-PCR-positive. Because none of the placental specimens tested by IHC from third trimester pregnancy losses (n = 4) or live births (n = 47) was IHC-positive, beginning in March 2016, IHC testing of these specimen types was no longer routinely performed. Among 546 live births, placental tissues from 60 (11%) were RT-PCR positive for Zika virus, including 38/363 (10%) from pregnancies with recent unspecified maternal flavivirus infection and 9/86 (10%) with negative maternal Zika virus IgM, where possible maternal exposure occurred >12 weeks before serum collection (after which time maternal Zika virus IgM antibodies might have waned) (5) ( Table 2) . Zika virus RT-PCR was negative on placental tissues from 34/47 (72%) live births with confirmed recent maternal Zika virus infection, and from all three live births in which the infant had confirmed congenital Zika virus infection based on infant testing. Among live births with no evidence of maternal Zika virus infection (n = 14) or no maternal clinical specimens tested (n = 34), none was tissue RT-PCR-positive. Overall, Zika virus RT-PCR was positive on placental tissues from 47/482 (10%) live births without a confirmed diagnosis by Zika virus testing on maternal or infant clinical specimens, confirming a diagnosis of recent maternal Zika virus infection (Figure) .
Placental or fetal tissues from 18 (22%) of the 81 pregnancy losses tested positive for Zika virus by RT-PCR, including 4/13 (31%) with recent unspecified maternal flavivirus infection, 2/18 (11%) with negative maternal Zika virus IgM, where possible maternal exposure occurred >12 weeks before serum collection, and 1/16 (6%) with no maternal clinical samples tested (Table 2) . Among 14 pregnancy losses with no evidence of maternal Zika virus infection, no placental or fetal tissues tested RT-PCR-positive. Ten of 28 (36%) first trimester pregnancy losses and 5/17 (29%) third trimester pregnancy losses were tissue RT-PCR-positive, compared with only 3/35 (9%) second trimester losses (Table 2 ). However, 13/28 (46%) first trimester pregnancy losses had evidence of confirmed recent maternal Zika virus infection from clinical specimens, compared with 5/35 (14%) of second trimester and 1/17 (6%) third trimester pregnancy losses.
Among the 627 completed pregnancies included in this report, 449 (72%) were included in the USZPR (Table 2) . Thirty live births were reported to have possible Zika virus-associated birth defects. Sixteen of these (53%) were Applies to results of testing on infant or fetal clinical specimens (e.g., serum, cord blood, urine, cerebrospinal fluid, amniotic fluid), however if infant PRNT titers not available, maternal serum PRNT titers were used. Only includes results of Zika virus clinical laboratory testing conducted in the United States and U.S. territories. § § Trimester of infection or possible exposure is based on symptom onset date for symptomatic pregnant women, and for asymptomatic women was based on trimester(s) of suspected vectorborne or sexual exposure. Periconceptional exposure only is defined as infection or possible exposure during the 8 weeks before conception (6 weeks before and 2 weeks after the first day of the last menstrual period). ¶ ¶ U.S. Zika Pregnancy Registry inclusion criteria = Pregnant women with laboratory evidence of Zika virus infection (positive or equivocal test results, regardless of whether they have had symptoms) and periconceptionally, prenatally, or perinatally exposed infants born to these women, and infants with laboratory evidence of congenital Zika virus infection (positive or equivocal test results, regardless of whether they had symptoms) and their mothers (https://www.cdc.gov/zika/reporting/registry.html). *** Birth defects include those that met the U.S. Zika Pregnancy Registry surveillance case definition for birth defects potentially associated with Zika virus infection during pregnancy as of May 18, 2017. These birth defects include brain abnormalities and/or microcephaly, intracranial calcifications, ventriculomegaly, neural tube defects and other early brain malformations, eye abnormalities, or other consequences of central nervous system dysfunction including arthrogryposis (joint contractures), clubfoot, congenital hip dysplasia, and congenital deafness (https://www.cdc.gov/zika/geo/pregnancy-outcomes.html). Placental tissue RT-PCR testing was positive in a relatively low proportion of live births with recent unspecified maternal flavivirus infection (10%) or negative maternal Zika virus IgM on serum collected >12 weeks after possible exposure (10%). Placental testing might provide additional diagnostic information and can continue to be considered in these scenarios (https://www.cdc.gov/zika/pdfs/ placental-testing-guidance.pdf), depending on the availability of public health resources. The yield of Zika virus testing of placental tissues should continue to be reassessed as additional data are collected.
FIGURE. Zika virus placental tissue RT-PCR results, among live births with neither clinical laboratory evidence of confirmed recent Zika virus infection on maternal testing nor confirmed congenital Zika virus infection on infant testing
Placental tissues have both maternal and fetal components, and Zika RT-PCR cannot discriminate between viral RNA from maternal and fetal areas (9) . Although placental testing cannot confirm or exclude congenital Zika virus infection, infants might be more likely to receive appropriate clinical evaluation when a mother has confirmed recent Zika virus infection. Negative placental RT-PCR results do not rule out maternal or congenital Zika virus infection; evaluation of pregnant women and infants for Zika virus in accordance with CDC guidance is essential to direct appropriate infant clinical management and follow-up (3, 4) . Infant Zika virus testing and neuroimaging should not be delayed while results of placental testing are pending.
Among live births with possible Zika virus-associated birth defects reported to the USZPR and included in this analysis, 53% were Zika virus RT-PCR-positive on placental tissues. The implications of a positive placental Zika virus RT-PCR for infant clinical outcomes are currently unknown. However, further study could explore the relationship between the presence of Zika virus RNA in placental specimens, fetal infection, and development of possible Zika virus-associated birth defects.
In this report, Zika virus IHC was only positive on fetal and placental tissues from first and second trimester pregnancy losses. Zika virus IHC-positivity in brain tissues from infant deaths has been reported in other studies (9, 10) . Although all IHC-positive cases were also RT-PCR-positive, IHC can provide valuable insight into viral localization and pathogenesis in pregnancy losses and infant deaths.
The findings in this report are subject to at least five limitations. First, a negative Zika virus RT-PCR on placental tissues does not exclude maternal Zika virus infection. Factors that could lead to false-negative results include levels of viral RNA below the limit of assay detection, variability in tissue sampling, and degradation of viral RNA because of insufficient tissue fixation or prolonged formalin-fixation. † † Second, pregnancy outcomes in this analysis might not be representative of all pregnancies with possible Zika virus exposure, maternal Zika virus infection, or Zika virus-associated birth defects in the United States. Pregnancies ending in a loss or with fetuses or infants with birth defects might be more likely to have tissue specimens submitted, particularly among pregnancies with negative maternal Zika virus IgM >12 weeks after possible exposure. Third, possible testing bias limits the ability to compare placental test results by results of infant clinical laboratory testing, because infants with possible Zika virus-associated birth defects might be more likely to have Zika virus testing performed. Fourth, the approach to testing of placental and fetal tissues changed over time, which might have resulted in variability in testing bias over the reporting period. Changes included routinely testing tissue specimens for completed pregnancies where maternal Zika virus IgM was negative >12 weeks after possible exposure (beginning in August 2016) (3, 4) , and focusing testing of placental specimens from live births on those without a confirmed recent maternal Zika virus infection diagnosis (https://www.cdc.gov/zika/pdfs/placental-testingguidance.pdf ). Finally, clinical, epidemiologic, and laboratory information reflects data reported to USZPR and CDC's IDPB as of the date of this report, and might be incomplete. † † Recommendations for specimen collection and submission are available at https://www.cdc.gov/zika/laboratories/test-specimens-tissues.html.
Summary
What is already known about this topic?
Zika virus infection during pregnancy can cause microcephaly and other brain abnormalities. Diagnosis of Zika virus infection is challenging because of serologic cross-reactivity with other related flaviviruses and limited duration of viremia. Zika virus RNA can be detected in placental and fetal tissues, which can provide an opportunity to diagnose maternal Zika virus infection and can be considered when maternal serologic testing is not definitive or is negative outside the optimal testing window.
What is added by this report?
In the 50 U. These findings describe the contributions of testing placental and fetal tissue specimens for Zika virus infection to the diagnosis of maternal infection. Although the proportion of live births with placental tissues positive for Zika virus by RT-PCR was low, tissue analysis can be valuable when maternal serologic testing either cannot differentiate between Zika virus and other related flaviviruses, or has been conducted >12 weeks after possible maternal exposure, and infant Zika virus testing is not definitive, negative, or not performed. Tissue analysis provides another opportunity to confirm maternal Zika virus infection, which can be important to both families and health care providers. However, because a positive Zika virus RT-PCR on placental tissues cannot distinguish between maternal and congenital infection, following current CDC guidance for clinical diagnostic testing and management of pregnant women with possible Zika virus exposure and infants with possible congenital Zika virus infection continues to be important (3, 4) .
